Article info

Download PDFPDF
0099: Analysis of Gemcitabine As Second or Third Line Therapy for Recurrent Ovarian Cancer or Primary Peritoneal Cancer

Authors

Citation

Nishimura M, Furumoto H, Abe A, et al
0099: Analysis of Gemcitabine As Second or Third Line Therapy for Recurrent Ovarian Cancer or Primary Peritoneal Cancer
Online issue publication 
December 17, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.